Good podcast? Give it some love!
Matt Pillar
Business Of BiotechEpisodes
Matt Pillar
Business Of Biotech
Good podcast? Give it some love!
Rate Podcast
Episodes of Business Of Biotech
Mark All
Search Episodes...
We love to hear from our listeners. Send us a message. Built on the back of hepatocyte growth factor discoveries by Harvard Drs. Reza Dana and Sunil Chauhan, ClarisBio is rewriting the ophthalmology rulebook. CEO Clark Atwell acknowledges that
We love to hear from our listeners. Send us a message. When we last caught up with Brian Culley, CEO at Lineage Cell Therapeutics, it was January, 2021. A pandemic was raging. His company was moving mountains to keep its OpRegen dry AMD clinica
We love to hear from our listeners. Send us a message. The cell therapy company Arcellx has, by any and every measure, been outperforming its peers. Its stock has rallied on the back of the strong performance of its multiple myeloma candidate,
We love to hear from our listeners. Send us a message. If there's anyone qualified to analyze an early-stage therapeutic technology and place bets with other people's money, it's scientist-turned-venture capitalist Jonathan Behr, Ph.D. He buil
We love to hear from our listeners. Send us a message. Just a few years ago, Daiichi Sankyo wasn't considered a player in the oncology therapeutics space, and it certainly wasn't a player in ADCs. But then, just a few years ago, who was? Fast f
We love to hear from our listeners. Send us a message. Mythic Therapeutics Chief Scientific Officer and co-founder Brian Fiske, Ph.D. broke some unwritten protocol with his rapid and multifaceted transition from academia to industry. He calls h
We love to hear from our listeners. Send us a message. This isn't your typical drug sponsor + CDMO story. In fact, CTMC's Jason Bock, Ph.D. says you shouldn't even classify his company a CDMO. He's not wrong. While some of the company's service
We love to hear from our listeners. Send us a message. Back by popular demand, biopharma industry opinionator extraordinaire Allan Shaw rejoins the Business of Biotech to expose the murky role Pharmacy Benefit Managers (PBMs) play in the last,
We love to hear from our listeners. Send us a message. From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in global tech hubs around the globe. Notably, he was co-
We love to hear from our listeners. Send us a message. As if Orna Therapeutics' CEO Thomas Barnes, CEO isn't a enough to draw you in to the Business of Biotech, we teamed up with Advancing RNA Editorial & Community Director Anna Rose Welch to c
We love to hear from our listeners. Send us a message. Novel technologies aren’t interesting to Rahul Kakkar, M.D. unless they help patients. Sounds rational, but it’s actually a unique perspective in a platform-crazed biotech industry. Dr. Kak
We love to hear from our listeners. Send us a message. This episode of the Business of Biotech begins with a personal story about my dad and the standard of care in bladder cancer, before shifting to the work that Dr. Bobby Reddy and his team a
We love to hear from our listeners. Send us a message. Ampersand Biomedicines CEO Jason Gardner, D.Phil. first took the leap from a global pharmaceutical giant to a startup at the forefront of transplant medicine innovation. Since that time, he
We love to hear from our listeners. Send us a message. We've really been looking forward to dropping this episode with Karen Harris, Chief Financial Officer and Head of Mission-Related Investing at the Alzheimer's Drug Discovery Foundation. Whi
We love to hear from our listeners. Send us a message. Few drug discovery and development concepts are as hyped, and as such, draw as much polarity from drug developers, as machine learning and artifical intelligence. One company on the bullish
We love to hear from our listeners. Send us a message. Gavin Samuels, M.D. found his work as an intensive care physician boring. After earning his M.D., he did that for a few years before moving into intensive care management roles. It wasn't u
We love to hear from our listeners. Send us a message. Rob Williamson's mind and hands have shaped more than 20 biotech startups, leading some to IPO and landing others firmly in Big Bio through acquisition by companies like Merck. Hanging arou
We love to hear from our listeners. Send us a message. In biotech, when "one of these things doesn't look like the other one," it can be a blessing or a curse. On one hand, scientific novelty is praised and rewarded. On the other, unfamiliarity
We love to hear from our listeners. Send us a message. Multimodal approaches to the delivery of radiologically active compounds have created a fertile environment to for players in the space to put on a precision medicine clinic, so to speak. W
We love to hear from our listeners. Send us a message. While you might be aware that Sail Biomedicines was just formed up in Q4 of last year, the product of Flagship Pioneering’s decision to merge Senda Biosciences and Laronde, two of its prog
We love to hear from our listeners. Send us a message. The concept of programmable biology is fueling a new breed of biotech, one that requires the marriage of computational and traditional science (and both computational and traditional scient
We love to hear from our listeners. Send us a message. Without doubt, the grand and collaborative experiment that was the mRNA COVID vaccine contributed mightily to the pandemic response and continues to save lives untold. It also demonstrated
We love to hear from our listeners. Send us a message. The Business of Biotech took a trip to San Francisco for the JP Morgan Healthcare Conference, that most target-richest of environments for those of us who like talking shop with biotech bui
We love to hear from our listeners. Send us a message. Success at multimodal, multi-indication, deep-pipelined Incyte—where commercial operations are as familiar as pre-discovery activity is—begins at the earliest opportunity to achieve researc
We love to hear from our listeners. Send us a message. We spend a lot of time talking with our guests about building biotech companies. That’s true of this episode too, but today we’re taking a step further with John Leonard, M.D., longtime CEO
Join Podchaser to...
- Rate podcasts and episodes
- Follow podcasts and creators
- Create podcast and episode lists
- & much more
Unlock more with Podchaser Pro
- Audience Insights
- Contact Information
- Demographics
- Charts
- Sponsor History
- and More!
- Account
- Register
- Log In
- Find Friends
- Resources
- Help Center
- Blog
- API
Podchaser is the ultimate destination for podcast data, search, and discovery. Learn More
- © 2024 Podchaser, Inc.
- Privacy Policy
- Terms of Service
- Contact Us